Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Darlow

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The Journal of Antimicrobial Chemotherapy|March 4, 2022
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' responseChristopher A Darlow, William Hope
The Journal of Antimicrobial Chemotherapy|December 30, 2021
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing EnterobacteralesChristopher A Darlow, William Hope
The Journal of Antimicrobial Chemotherapy|May 31, 2022
Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing EnterobacteralesChristopher A Darlow, William Hope
JAMA Internal Medicine|August 26, 2024
Reevaluating Piperacillin-Tazobactam MortalityChristopher A Darlow, Alessandro Gerada, William Hope
Expert Opinion on Drug Metabolism & Toxicology|November 7, 2024
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluationChristopher A Darlow, William Hope, Vineet Dubey
BMJ Case Reports|August 9, 2017
A spinal infection with <i>Staphylococcus pseudintermedius</i>Christopher A Darlow, Nikolaos Paidakakos, Murtuza Sikander, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 18, 2023
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainmentChristopher A Darlow, Neil Parrott, Richard W Peck, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 27, 2024
Susceptibility of OXA-48-like-producing Enterobacterales to flomoxefVictoria Owen, Nicholas Harper, Vineet Dubey, et al.
Infection|June 23, 2025
Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases settingChristopher A Darlow, Joseph Parsons, Danielle Lucy, et al.
The Journal of Infection|March 18, 2020
Microbial aetiology of brain abscess in a UK cohort: Prominent role of Streptococcus intermediusChristopher A Darlow, Nicholas McGlashan, Richard Kerr, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The Journal of Antimicrobial Chemotherapy|March 4, 2022
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' responseChristopher A Darlow, William Hope
The Journal of Antimicrobial Chemotherapy|December 30, 2021
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing EnterobacteralesChristopher A Darlow, William Hope
The Journal of Antimicrobial Chemotherapy|May 31, 2022
Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing EnterobacteralesChristopher A Darlow, William Hope
JAMA Internal Medicine|August 26, 2024
Reevaluating Piperacillin-Tazobactam MortalityChristopher A Darlow, Alessandro Gerada, William Hope
Expert Opinion on Drug Metabolism & Toxicology|November 7, 2024
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluationChristopher A Darlow, William Hope, Vineet Dubey
BMJ Case Reports|August 9, 2017
A spinal infection with <i>Staphylococcus pseudintermedius</i>Christopher A Darlow, Nikolaos Paidakakos, Murtuza Sikander, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 18, 2023
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainmentChristopher A Darlow, Neil Parrott, Richard W Peck, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 27, 2024
Susceptibility of OXA-48-like-producing Enterobacterales to flomoxefVictoria Owen, Nicholas Harper, Vineet Dubey, et al.
Infection|June 23, 2025
Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases settingChristopher A Darlow, Joseph Parsons, Danielle Lucy, et al.
The Journal of Infection|March 18, 2020
Microbial aetiology of brain abscess in a UK cohort: Prominent role of Streptococcus intermediusChristopher A Darlow, Nicholas McGlashan, Richard Kerr, et al.
Pageof 2